Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study

Table 2 Baseline characteristics

Variables	Adjuvant chemotherapy cycles	Not received (A)	7–8 or 10–12 cycles (B)	4–6 or 6–9 cycles (C)	≤3 or 5 cycles (D)
Variables	Adjuvant chemotherapy cycles	P	P	P	P
Age	Not received (A)		< 0.001	< 0.001	0.019
	7–8 or 10–12 cycles (B)	< 0.001		0.043	< 0.001
	4–6 or 6–9 cycles (C)	< 0.001	0.043		0.060
	≤3 or 5 cycles (D)	0.019	< 0.001	0.060
BMI	Not received (A)		0.008	0.356	0.095
	7–8 or 10–12 cycles (B)	0.008		0.080	0.650
	4–6 or 6–9 cycles (C)	0.356	0.080		0.361
	≤3 or 5 cycles (D)	0.095	0.650	0.361
Postoperative complications	Not received (A)		< 0.001	0.009	0.054
	7–8 or 10–12 cycles (B)	< 0.001		0.405	0.310
	4–6 or 6–9 cycles (C)	0.009	0.405		0.782
	≤3 or 5 cycles (D)	0.054	0.310	0.782
Tumor length/diameter	Not received (A)		0.361	0.474	0.029
	7–8 or 10–12 cycles (B)	0.361		0.893	0.001
	4–6 or 6–9 cycles (C)	0.474	0.893		0.004
	≤3 or 5 cycles (D)	0.029	0.001	0.004

ISSN: 1471-2407